En undersøgelse af deltagere med fedme eller overvægt med mindst én vægtrelateret komorbiditet (APRICUS)
En fase IIb randomiseret, dobbeltblind, placebokontrolleret undersøgelse for at evaluere effektiviteten, sikkerheden og tolerabiliteten af AZD6234 hos deltagere, der lever med fedme eller overvægt med komorbiditet
A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 compared with placebo, given once a week as subcutaneous injection for 36 weeks, in male and female participants of at least 18 years of age who are living with obesity (body mass index [BMI] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) and at least one weight-related comorbidity
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The study will comprise of:
A screening period of maximum 28 days
A treatment period of 36 weeks
A follow up period after last dose of study drug
This study will consist of 4 cohorts. Approximately 231 eligible participants will be randomized to AZD6234 or placebo
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Heidelberg, Australien, 3081
- Research Site
-
Maroochydore, Australien, 4556
- Research Site
-
Maroubra, Australien, 2035
- Research Site
-
Merewether, Australien, 2291
- Research Site
-
-
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 5G8
- Research Site
-
Sarnia, Ontario, Canada, N7T 4X3
- Research Site
-
Stouffville, Ontario, Canada, L4A1H2
- Research Site
-
Toronto, Ontario, Canada, M3J 0K2
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4N 2W2
- Research Site
-
Sherbrooke, Quebec, Canada, J1L 0H8
- Research Site
-
-
-
-
-
Hull, Det Forenede Kongerige, HU3 2PA
- Research Site
-
Leicester, Det Forenede Kongerige, Le5 4PW
- Research Site
-
Penarth, Det Forenede Kongerige, CF64 2XX
- Research Site
-
Rotherham, Det Forenede Kongerige, S65 1DA
- Research Site
-
-
-
-
Alabama
-
Mobile, Alabama, Forenede Stater, 36608
- Research Site
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85044
- Research Site
-
-
California
-
Long Beach, California, Forenede Stater, 90815
- Research Site
-
-
Florida
-
Hialeah, Florida, Forenede Stater, 33012
- Research Site
-
Largo, Florida, Forenede Stater, 33777
- Research Site
-
Orlando, Florida, Forenede Stater, 32825
- Research Site
-
Tampa, Florida, Forenede Stater, 33606
- Research Site
-
-
Georgia
-
Woodstock, Georgia, Forenede Stater, 30189
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46260
- Research Site
-
-
Maryland
-
Lutherville-Timonium, Maryland, Forenede Stater, 21093
- Research Site
-
-
Mississippi
-
Gulfport, Mississippi, Forenede Stater, 39503
- Research Site
-
Ridgeland, Mississippi, Forenede Stater, 39157
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Forenede Stater, 64111
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68134
- Research Site
-
-
New Hampshire
-
Portsmouth, New Hampshire, Forenede Stater, 03801
- Research Site
-
-
North Carolina
-
Statesville, North Carolina, Forenede Stater, 28625
- Research Site
-
-
South Carolina
-
North Charleston, South Carolina, Forenede Stater, 29405
- Research Site
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37938
- Research Site
-
-
Texas
-
Austin, Texas, Forenede Stater, 78731
- Research Site
-
Dallas, Texas, Forenede Stater, 75230
- Research Site
-
Port Arthur, Texas, Forenede Stater, 77642
- Research Site
-
San Antonio, Texas, Forenede Stater, 78249
- Research Site
-
San Antonio, Texas, Forenede Stater, 78231
- Research Site
-
-
-
-
-
Chūōku, Japan, 103-0027
- Research Site
-
Chūōku, Japan, 104-0031
- Research Site
-
Shinjuku-ku, Japan, 160-0008
- Research Site
-
Suita-shi, Japan, 565-0853
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults ≥ 18 years of age
- BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
- A stable body weight for 3 months prior to Screening (±5% body weight change)
Exclusion Criteria:
- Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
- Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
- Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
- History of type 1 diabetes mellitus or T2DM
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm 1
Dose 1 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Eksperimentel: Arm 2
Dose 2 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Eksperimentel: Arm 3
Dose 3 |
IMP injected subcutaneously, once a week. Unit dose strength as per CSP |
|
Placebo komparator: Arm 4
Placebo - Dose matched with each Experimental arm |
Placebo matching IMP dose injected subcutaneously, once a week. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent change in body weight from baseline to week 26
Tidsramme: 26 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
26 weeks
|
|
Weight loss ≥ 5% from baseline weight to week 26
Tidsramme: 26 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
26 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Weight loss ≥ 5% from baseline to week 36
Tidsramme: 36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 5% from baseline |
36 weeks
|
|
Weight loss ≥ 10% from baseline to week 36
Tidsramme: 36 weeks
|
To determine whether AZD6234 is superior to placebo in participants with weight loss ≥ 10% from baseline |
36 weeks
|
|
Percent change in body weight from baseline to week 36
Tidsramme: 36 weeks
|
To determine whether AZD6234 is superior to placebo for weight loss |
36 weeks
|
|
Absolute change in body weight (kg) from baseline to week 26 and week 36
Tidsramme: week 26 and week 36
|
To determine whether AZD6234 is superior to placebo for absolute weight loss |
week 26 and week 36
|
|
AZD6234 plasma concentrations
Tidsramme: Week 43
|
To characterise the PK of AZD6234 |
Week 43
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- D8750C00004
- 2024-514000-13-00 (Registry Identifier: EU CT number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-delingstidsramme
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-delingsadgangskriterier
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .